BMN 165
Biological
BioMarin Pharmaceutical Inc.
Total Payments
$6.3M
Transactions
918
Doctors
43
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $1.3M | 170 | 21 |
| 2017 | $5.0M | 748 | 31 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.9M | 598 | 93.6% |
| Consulting Fee | $157,199 | 27 | 2.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $99,801 | 54 | 1.6% |
| Travel and Lodging | $91,103 | 149 | 1.5% |
| Honoraria | $20,500 | 12 | 0.3% |
| Food and Beverage | $19,505 | 77 | 0.3% |
| Grant | $12,000 | 1 | 0.2% |
Payments by Type
Research
$5.9M
598 transactions
General
$400,108
320 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU Prism302) | BioMarin Pharmaceutical Inc. | $3.7M | 0 |
| Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU Prism302 | BioMarin Pharmaceutical Inc. | $976,931 | 0 |
| Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU PAL-003) | BioMarin Pharmaceutical Inc. | $457,788 | 0 |
| Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU (Prism302) | BioMarin Pharmaceutical Inc. | $387,642 | 0 |
| Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU PAL-003 | BioMarin Pharmaceutical Inc. | $185,962 | 0 |
| Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003) | BioMarin Pharmaceutical Inc. | $81,654 | 0 |
| Phase 3 substudy enrolling approximately 100 subjects aged 18 to 70 years old with PKU who are concurrently participating in the 165-302 study | BioMarin Pharmaceutical Inc. | $36,091 | 0 |
| A Non-Interventional Observational Study of Pegvaliase-Naive Adults with Phenylketonuria PKU Concept Elicitation and Cognitive Interviews | BioMarin Pharmaceutical Inc. | $34,586 | 0 |
| A Phase 3, Open-Label, Randomized, Multi-Center Study to Assess the Safety and Tolerability of an Induction, Titration, and Maintenance Dose Regimen of BMN 165 Self Administered by Adults With Phenylketonuria Not Previously Treated with BMN 165 | BioMarin Pharmaceutical Inc. | $12,858 | 0 |
| A Non-Interventional Observational Study of Pegvaliase-Naive Adults with Phenylketonuria PKU) Concept Elicitation and Cognitive Interviews | BioMarin Pharmaceutical Inc. | $11,046 | 0 |
| Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria PKU | BioMarin Pharmaceutical Inc. | $4,997 | 0 |
| An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated W- BMN 165-Prism301 | BioMarin Pharmaceutical Inc. | $4,590 | 0 |
| A Four-Part, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Discontinuation Study to Evaluate the Efficacy and Safety of Subcutaneous Injections of BMN 165 Self Administered by Adults with Phenylketonuria | BioMarin Pharmaceutical Inc. | $669.00 | 0 |
Top Doctors Receiving Payments for BMN 165 — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Internal Medicine | Los Angelas, CA | $3,696 | 5 |
| , M.D., PH.D | Pediatrics | Baltimore, MD | $3,627 | 5 |
| , MD | Endocrinology, Diabetes & Metabolism | Dallas, TX | $3,576 | 5 |
| , M.D | Clinical Genetics (M.D.) | Lexington, KY | $3,484 | 6 |
| , MD | Clinical Genetics (M.D.) | Orlando, FL | $3,342 | 5 |
| , MD | Pediatrics | Waltham, MA | $3,000 | 1 |
| , M.D | Clinical Genetics (M.D.) | Boston, MA | $3,000 | 1 |
| , M.D | Clinical Genetics (M.D.) | Galveston, TX | $2,945 | 3 |
| , MD | Rheumatology | Saint Louis, MO | $2,400 | 2 |
| , MD, PHD | Pediatric Infectious Diseases | Philadelphia, PA | $2,250 | 1 |
| , MD | Clinical Genetics (M.D.) | Houston, TX | $2,037 | 3 |
| , MD | Allergy & Immunology | Germantown, TN | $1,750 | 2 |
| , M.D | Nephrology | Columbus, OH | $1,400 | 1 |
| , MD | Pediatric Gastroenterology | Oakland, CA | $126.75 | 2 |
| , M.D | Clinical Genetics (M.D.) | Stony Brook, NY | $56.94 | 2 |
| , M.D., PH.D | Pediatrics | Haworth, NJ | $31.40 | 1 |
| , MD | Pediatrics | Newark, NJ | $26.23 | 1 |
| , M.D | Clinical Biochemical Genetics | Fort Worth, TX | $17.57 | 1 |
| , MD | Clinical Genetics (M.D.) | Oklahoma City, OK | $10.20 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $6.3M
- Total Doctors 43
- Transactions 918
About BMN 165
BMN 165 is a biological associated with $6.3M in payments to 43 healthcare providers, recorded across 918 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2017 to 2018. In 2018, $1.3M was paid across 170 transactions to 21 doctors.
The most common payment nature for BMN 165 is "Unspecified" ($5.9M, 93.6% of total).
BMN 165 is associated with 13 research studies, including "Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU Prism302)" ($3.7M).